Targeted Covalent Inhibitors for Drug Design
The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent interaction of a ligand with its biological target, a targeted covalent inhibitor (TCI) is designed such that the initial, reversible association is followed by the formation of a covalent bond between an electrophile on the ligand and a nucleophilic center in the protein. Although this approach offers a variety of potential benefits (high potency and extended duration of action), concerns over the possible toxicological consequences of protein haptenization have hindered the development of the TCI concept. Recently, approaches to mitigate the risk of serious adverse reactions to this new class of agent have emerged, thus stimulating interest in the field and leading to authorization of the first cadre of TCIs to be marketed. The covalent inhibitor approach is rapidly gaining acceptance as a valuable tool in drug discovery, and is poised to make a major impact on the design of enzyme inhibitors and receptor modulators.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the oxidation of drugs such as furosemide, isoniazid, acetaminophen, halothane, and model hepatotoxins via cytochrome P-450 can lead to hepatotoxic effects in animals and humans [131, 132].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [132]
Citations
Cites
The growing applications of click chemistry
Moses, J. E., & Moorhouse, A. D. (2007) · Chem. Soc. Rev. · doi:10.1039/b613014n · Cited by 2,367
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Self-citationCommon and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity
Guengerich, F. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002583 · Cited by 1,655
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Self-citationStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Self-citation
Research works printed but not linked: 7
- Parmar S., 2014, Pharm. Ther., 39, 483
- Johansson M. H., 2012, Mini-Rev. Med. Chem., 12, 1330
- Campuzano I. D. G., 2015, J. Biomol. Screening, 1
- Guerciolini R., 1997, Int. J. Obes., 21, 12
- Kumar S., 2008, Curr. Opin. Drug Discovery Dev., 11, 43
- Strelevitz T. J., 2015, Drug Metab. Rev., 47, 59
- The Wall Street Journal December 2 2015.
Cited by
Items 601–618 of 618
BindingDB Entry 50016591: Covalent Modification of the JH2 Domain of Janus Kinase 2.
BindingDB (2023) · UC San Diego · doi:10.7270/q2d50rzq
BindingDB (2024) · UC San Diego · doi:10.7270/q25d8x66
BindingDB Entry 50023549: Classifying covalent protein binders by their targeted binding site.
BindingDB (2026) · UC San Diego · doi:10.7270/q2xk8mgm
BindingDB Entry 50006866: Discovery and Development of a Series of Pyrazolo[3,4-
BindingDB (2021) · UC San Diego · doi:10.7270/q2kp85d8
BindingDB (2026) · UC San Diego · doi:10.7270/q2x63swc
BindingDB (2022) · UC San Diego · doi:10.7270/q28s4tqw
BindingDB Entry 50002046: Small molecule inhibitors of anthrax edema factor.
BindingDB (2020) · UC San Diego · doi:10.7270/q25d8vd2
Terada, R., Watanabe, R., Komura, H., & Mizuguchi, K. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00696
Metadata
- Authors
- Baillie, T. A.
- Affiliations
- University of Washington (US)
- Corresponding author
- Baillie, Thomas A.
- ORCID
- Baillie, Thomas A.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2016-08-19
- Volume
- 55
- Issue
- 43
- Pages
- 13408-13421
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2517550655
- Cited by
- 578
- References
- 118
- Citations by year
- 2026: 55 · 2025: 77 · 2024: 66 · 2023: 46 · 2022: 49 · 2021: 76 · 2020: 72 · 2019: 52 · 2018: 46 · 2017: 31 · 2016: 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- targeted covalent inhibitors, covalent drug design, drug toxicity, enzyme inhibitors, receptor modulators, drug discovery, non-covalent binding
- MeSH terms
- Animals, Enzyme Inhibitors, Humans, Ligands, Protein Kinases, Drug Design, Molecular Structure, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.